GLP-1
Heidelberg Pharma AG reported on the first nine months of fiscal year 2019 and the Group’s financial figures.
NBE-Therapeutics AG, a biopharmaceutical company developing best-in-class, immune-stimulatory antibody drug conjugates (iADCs™), announces the appointment of Dr. Steffen Heeger as Chief Medical Officer (CMO).
Companies from across the globe share information on their business and pipelines.
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces its first half 2019 financial results.
The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly
BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
Novo Nordisk’s oral-semaglutide for type 2 diabetes snagged approval from the U.S. Food and Drug Administration late Friday, marking it as the first such treatment to be approved in pill form.
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
Primary results showed significantly greater reduction in blood sugar levels over 26 weeks after switching to Soliqua® / Suliqua® 1 vs staying on daily or weekly GLP-1 receptor agonist
Adocia announced that it will deliver an oral presentation covering its ADO09 product at the 55th Annual Meeting of the European Association for the Study of Diabetes, being held September 16-20, 2019 in Barcelona, Spain.
PRESS RELEASES